Company intelligence / Profile preview

Evexta Bio

Ownership: Private
Development stage: Phase 2

Overview

Evexta Bio is advancing rupitasertib, a selective oral inhibitor of S6K and AKT1/AKT3, to Phase 2 clinical trials in advanced breast cancer. The company received positive feedback from FDA following a Type B meeting, enabling them to move forward with clinical development. Phase 2 clinical trial was on track to start in Q4 2024.

Therapeutic areas: OncologyHematology
Modalities: Small molecule drugsAntibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

4 assets

rupitasertib

3 more assets in the full pipeline.

Partnerships

Merck KGaA (Darmstadt, Germany)CNRSPaoli-Calmettes Institute (Marseille, France)

Beyond the preview

Go deeper on Evexta Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evexta Bio.